Maziar Sadri

Maziar Sadri practices at Atrium Healthcare Group in Annandale, Virginia.

Maziar Sadri's NPI, 1922487198, was assigned on May 21, 2015. Maziar Sadri holds Virginia license 0101264564.

Maziar Sadri's primary practice is Atrium Healthcare Group, at 7501 Little River Tpke Ste 303, Annandale, VA 22003-2923. The practice phone is (703) 256-4141.

Maziar Sadri's primary practice is Atrium Healthcare Group in Annandale, Virginia. Maziar Sadri is also affiliated with Inova Fairfax Hospital. The medical group on file is Patient First. Dmand AI also links Maziar Sadri to 3 more home health agencies, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Maziar Sadri practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Maziar Sadri's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Maziar Sadri is licensed in Virginia.

CMS data shows 1,521 Medicare services from Maziar Sadri across 14 procedure codes in 2024, for 212 Medicare patients. Medicare paid $128,872 for them. Every service was in an office.

CMS counts 212 Medicare patients who saw Maziar Sadri in 2024. The largest group is 75 to 84, with 82 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Maziar Sadri's median patient age at 58, with 57% women.

In 2024, Maziar Sadri wrote 3,136 Medicare Part D claims for 227 patients. 89% of them were for generic drugs. CMS names the drug for 2,649 of them, across 67 drugs with 11 or more claims each, at $222,136 in total drug cost. In 2023, CMS named 1,123 claims across 42 drugs.

Maziar Sadri accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Maziar Sadri as offering telehealth.

CMS Open Payments shows 81 general payments to Maziar Sadri from 12 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 99% of the total. Amgen Inc. paid the most, $969.